136 related articles for article (PubMed ID: 37565580)
21. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma.
van Besien K; Ha CS; Murphy S; McLaughlin P; Rodriguez A; Amin K; Forman A; Romaguera J; Hagemeister F; Younes A; Bachier C; Sarris A; Sobocinski KS; Cox JD; Cabanillas F
Blood; 1998 Feb; 91(4):1178-84. PubMed ID: 9454747
[TBL] [Abstract][Full Text] [Related]
22. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma.
Chihara D; Fanale MA; Miranda RN; Noorani M; Westin JR; Nastoupil LJ; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Turturro F; Lee HJ; Neelapu SS; Rodriguez MA; Wang M; Fowler NH; Davis RE; Medeiros LJ; Oki Y
PLoS One; 2018; 13(3):e0191461. PubMed ID: 29538376
[TBL] [Abstract][Full Text] [Related]
23. Improved method to stratify lymphoma patients with risk of secondary central nervous system involvement: A multicenter retrospective analysis.
Lang M; Feng Y; Meng X; Zhao J; Song Z; Qian Z; Qiu L; Zhou S; Liu X; Li L; Yang H; Song Y; Li W; Zhang H
Hematol Oncol; 2023 Apr; 41(2):239-247. PubMed ID: 34564882
[TBL] [Abstract][Full Text] [Related]
24. Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.
Karschnia P; Arrillaga-Romany IC; Eichler A; Forst DA; Gerstner E; Jordan JT; Ly I; Plotkin SR; Wang N; Martinez-Lage M; Winter SF; Tonn JC; Rejeski K; von Baumgarten L; Cahill DP; Nahed BV; Shankar GM; Abramson JS; Barnes JA; El-Jawahri A; Hochberg EP; Johnson PC; Soumerai JD; Takvorian RW; Chen YB; Frigault MJ; Dietrich J
Neuro Oncol; 2023 Dec; 25(12):2239-2249. PubMed ID: 37402650
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma.
Zhang H; Yan Z; Wang Y; Qi Y; Hu Y; Li P; Cao J; Zhang M; Xiao X; Shi M; Xia J; Ma S; Qiao J; Li H; Pan B; Qi K; Cheng H; Sun H; Zhu F; Sang W; Li D; Li Z; Zheng J; Zhao M; Liang A; Huang H; Xu K
Front Immunol; 2022; 13():965224. PubMed ID: 36059496
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological analysis of primary central nervous system NK/T cell lymphoma: rare and localized aggressive tumour among extranasal NK/T cell tumours.
Miyata-Takata T; Takata K; Kato S; Hu LM; Noujima-Harada M; Chuang SS; Sato Y; Maeda Y; Yoshino T
Histopathology; 2017 Aug; 71(2):287-295. PubMed ID: 28342197
[TBL] [Abstract][Full Text] [Related]
27. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
28. Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma.
Yi JH; Kim JH; Baek KK; Lim T; Lee DJ; Ahn YC; Kim K; Kim SJ; Ko YH; Kim WS
Ann Oncol; 2011 Jul; 22(7):1636-1643. PubMed ID: 21220520
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review.
Wu X; Zhang X; Xun R; Liu M; Sun Z; Huang J
Front Immunol; 2021; 12():693200. PubMed ID: 34290712
[TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003-2018).
Seegobin K; Li Z; Alhaj Moustafa M; Majeed U; Wang J; Jiang L; Kuhlman J; Menke D; Li K; Kharfan-Dabaja MA; Ayala E; Iqbal M; Nowakowski GS; Habermann TM; Witzig TE; Johnston P; Thompson C; Ansell S; Tun HW
Am J Hematol; 2022 Sep; 97(9):1150-1158. PubMed ID: 35713565
[TBL] [Abstract][Full Text] [Related]
31. An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement.
Sunderland AJ; Steiner RE; Al Zahrani M; Pinnix CC; Dabaja BS; Gunther JR; Nastoupil LJ; Jerkeman M; Joske D; Cull G; El-Galaly T; Villa D; Cheah CY
Cancer Med; 2020 Jan; 9(2):663-670. PubMed ID: 31808316
[TBL] [Abstract][Full Text] [Related]
32. Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes.
Lim T; Kim SJ; Kim K; Lee JI; Lim DH; Lee DJ; Baek KK; Lee HY; Han B; Uhm JE; Ko YH; Kim WS
Ann Hematol; 2011 Dec; 90(12):1391-8. PubMed ID: 21479535
[TBL] [Abstract][Full Text] [Related]
33. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA; Olszewski AJ
Curr Treat Options Oncol; 2018 Jun; 19(8):38. PubMed ID: 29931605
[TBL] [Abstract][Full Text] [Related]
34. Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study.
Ellin F; Landström J; Jerkeman M; Relander T
Blood; 2015 Jul; 126(1):36-41. PubMed ID: 25957393
[TBL] [Abstract][Full Text] [Related]
35. Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B-cell lymphoma in the rituximab era.
Vassilakopoulos TP; Panitsas F; Mellios Z; Apostolidis J; Michael M; Gurion R; Ferhanoglu B; Hatzimichael E; Karakatsanis S; Dimou M; Kalpadakis C; Katodritou E; Leonidopoulou T; Kotsianidis I; Giatra H; Kanellias N; Sayyed A; Tadmor T; Akay OM; Angelopoulou MK; Horowitz N; Bakiri M; Pangalis GA; Panayiotidis P; Papageorgiou SG
Hematol Oncol; 2023 Feb; 41(1):97-107. PubMed ID: 36314897
[TBL] [Abstract][Full Text] [Related]
36. Central Nervous System Involvement in Peripheral T Cell Lymphoma.
Chihara D; Oki Y
Curr Hematol Malig Rep; 2018 Feb; 13(1):1-6. PubMed ID: 29374824
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of Autologous Stem Cell Transplantation as a Consolidative Strategy for the Treatment of Primary and Isolated Secondary Central Nervous System Diffuse Large B Cell Lymphomas.
Sahin U; Gokmen A; Soydan E; Urlu SM; Merter M; Gokgoz Z; Arslan O; Ozcan M
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e1-e13. PubMed ID: 36344419
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance.
Wight JC; Yue M; Keane C; Johnston A; Linton K; Chin C; Wai SH; Talaulikar D; Gasiorowski R; Cheah CY; Gregory GP; Dickinson M; Minson A; Coombes C; Ku M; Lam S; Hawkes EA
Br J Haematol; 2019 Oct; 187(2):174-184. PubMed ID: 31236941
[TBL] [Abstract][Full Text] [Related]
39. Biology and genetics of extranodal mature T-cell and NKcell lymphomas and lymphoproliferative disorders.
Lewis NE; Zhou T; Dogan A
Haematologica; 2023 Dec; 108(12):3261-3277. PubMed ID: 38037802
[TBL] [Abstract][Full Text] [Related]
40. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy.
Martín-Martín L; Almeida J; Pomares H; González-Barca E; Bravo P; Giménez T; Heras C; Queizán JA; Pérez-Ceballos E; Martínez V; Alonso N; Calvo C; Álvarez R; Caballero MD; Orfao A
Oncotarget; 2016 Mar; 7(9):10174-81. PubMed ID: 26840087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
